TM9SF1: A Potential Drug Target and Biomarker (G10548)

Target Name: TM9SF1

NCBI ID: G10548

TM9SF1

TM9SF1: A Potential Drug Target and Biomarker

TM9SF1, also known as OTTHUMP00000164699, is a gene that encodes a protein involved in the development and maintenance of tissues, particularly the brain. The identification of this gene as a potential drug target and biomarker has significant implications for the pharmaceutical industry, as well as basic biological research. In this article, we will provide an overview of TM9SF1, its potential drug target status, and its potential as a biomarker.

Overview of TM9SF1

TM9SF1 is a gene that encodes a protein with 214 amino acid residues. The protein has been shown to play a critical role in the development and maintenance of tissues, including the brain. TM9SF1 has been shown to localize to the endoplasmic reticulum (ER) and to interact with the protein transmembrane protease (TMPR2). TM9SF1 has also been shown to be involved in the regulation of cell growth, apoptosis, and inflammation.

Potential Drug Target Status

TM9SF1 has been identified as a potential drug target due to its involvement in the regulation of cell growth, apoptosis, and inflammation. Many diseases, including cancer, neurodegenerative disorders, and autoimmune diseases, are characterized by disruptions in cell growth and apoptosis. TM9SF1 has been shown to play a critical role in regulating cell growth and apoptosis, which suggests that it may be a useful target for the development of new pharmaceuticals for these diseases.

In addition, TM9SF1 has been shown to interact with the protein transmembrane protease (TMPR2). TMPR2 is a protein that has been shown to play a critical role in the regulation of cell growth and apoptosis. The interaction between TM9SF1 and TMPR2 suggests that TM9SF1 may be a useful target for the development of drugs that target TMPR2.

Potential as a Biomarker

TM9SF1 has also been shown to be involved in the regulation of inflammation. Inflammation is a critical response of the immune system to harmful stimuli, and it is often associated with a range of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. TM9SF1 has been shown to play a critical role in regulating inflammation, which suggests that it may be a useful biomarker for the diagnosis and treatment of these diseases.

In addition, TM9SF1 has been shown to have potential as a biomarker for cancer. TM9SF1 has been shown to be involved in the regulation of cell growth and apoptosis in cancer cells. The interaction between TM9SF1 and TMPR2 also suggests that TM9SF1 may be a useful target for the development of drugs that target TMPR2 in cancer cells.

Conclusion

TM9SF1 is a gene that encodes a protein involved in the development and maintenance of tissues, particularly the brain. The identification of TM9SF1 as a potential drug target and biomarker has significant implications for the pharmaceutical industry and basic biological research. Further research is needed to fully understand the role of TM9SF1 in the regulation of cell growth, apoptosis, and inflammation, as well as its potential as a biomarker for cancer.

Protein Name: Transmembrane 9 Superfamily Member 1

Functions: Plays an essential role in autophagy

The "TM9SF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TM9SF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets